Multiple Sclerosis

Video game therapy was found to have a minor impact on postural balance in patients with multiple sclerosis (MS); however, more research is needed to determine whether it should be recommended in clinical practice, investigators concluded.

A recent study found patients with multiple sclerosis (MS) experienced depressive and anxiety symptoms during the COVID-19 pandemic prior to vaccine rollout, especially among those who tested positive for COVID-19.

A study confirmed that many online resources showed inconsistencies or omissions compared with established guidelines related to physical activity and exercise training, which are known to provide clinical benefits for patients with multiple sclerosis (MS).

Survey results shows that health care professionals found a digital tool to be useful and useable in facilitating discussions with patients with multiple sclerosis (MS) about whether they are showing signs of disease progression.

Some immunosuppressive medications, particularly anti-CD20 monoclonal antibodies, were found to reduce antibodies designed to protect against SARS-CoV-2 infection in patients with multiple sclerosis (MS) who have recovered from COVID-19, investigators concluded.

Patients with multiple sclerosis (MS) who had a higher education level experienced less cognitive impairment related to their disease than patients with a lower education level, investigators concluded.

Misconceptions about the safety and necessity of vaccines were cited as the main reasons for lower-than-recommended vaccination rates among patients with multiple sclerosis (MS), according to new research.

Non-white patients with multiple sclerosis (MS), particularly African American and Hispanic American patients, were found to experience a higher level of overall disability and more severe symptoms, highlighting current disparities in this disease.

In a survey, researchers indicated that the COVID-19 pandemic has placed extra barriers, including a lack of accessibility to patients and competing responsibilities, that have resulted in halts or delays to research on multiple sclerosis (MS) rehabilitation and quality of life.

Patients who have both multiple sclerosis (MS) and depression may have a higher risk of death and vascular disease compared with people who only have 1 or neither of those conditions.

Patients with multiple sclerosis (MS) who have recovered from COVID-19 and received the B-cell depleting therapy ocrelizumab for at least 1 year were observed to still have T-cell responses.

Investigators found that biomarkers for neurodegeneration and inflammation could also aid providers in detecting declines in cognition and information processing speed in patients with multiple sclerosis (MS) over a 5-year period.

The single-leg heel test was able to differentiate between weaker and stronger limbs in patients with multiple sclerosis (MS) and in healthy controls, suggesting that the test could prove useful for identifying impaired muscle performance.

Using artificial intelligence (AI) effectively may help to revolutionize the diagnosis, monitoring, and treatment of multiple sclerosis (MS), as well as optimizing understanding of the immune-mediated disease.

Results of an observational study suggest retinal nerve fiber layer atrophy and the presence of oligoclonal bands may serve as biomarkers for cognitive decline in patients with multiple sclerosis (MS).

Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.

Key opinion leaders in MS provide closing thoughts on the future of MS treatment including digital therapeutics, new generics, and pipeline drugs on the horizon.

Thomas Leist, MD and Darin Okuda, MD describe the current landscape of disease guidelines and algorithms in MS treatment.

Investigators explored the associations between body weight and pediatric-onset multiple sclerosis.

Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.

Experts in MS discuss the challenges related to treatment selection and management when MS disease progression occurs.

Thomas Leist, MD and Darin Okuda, MD discuss clinical trials supporting the use of high efficacy MS therapies: ocrelizumab, ofatumumab, and cladribine.

Research indicates those with pediatric-onset multiple sclerosis (POMS) may have reduced memory performance compared with healthy controls.

Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.

MS specialists Darin Okuda, MD and Thomas Leist, MD discuss the viability of a generic-first treatment approach in MS.